Cargando…

Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production

Deficiencies in either growth hormone (GH) or insulin-like growth factor 1 (IGF-1) are associated with reductions in bone size during growth in humans and animal models. Liver-specific IGF-1-deficient (LID) mice, which have 75% reductions in serum IGF-1, were created previously to separate the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Courtland, Hayden-William, Sun, Hui, Beth-On, Mordechay, Wu, Yingjie, Elis, Sebastien, Rosen, Clifford J, Yakar, Shoshana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Subscription Services, Inc., A Wiley Company 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179330/
https://www.ncbi.nlm.nih.gov/pubmed/20928887
http://dx.doi.org/10.1002/jbmr.265
_version_ 1782212508560392192
author Courtland, Hayden-William
Sun, Hui
Beth-On, Mordechay
Wu, Yingjie
Elis, Sebastien
Rosen, Clifford J
Yakar, Shoshana
author_facet Courtland, Hayden-William
Sun, Hui
Beth-On, Mordechay
Wu, Yingjie
Elis, Sebastien
Rosen, Clifford J
Yakar, Shoshana
author_sort Courtland, Hayden-William
collection PubMed
description Deficiencies in either growth hormone (GH) or insulin-like growth factor 1 (IGF-1) are associated with reductions in bone size during growth in humans and animal models. Liver-specific IGF-1-deficient (LID) mice, which have 75% reductions in serum IGF-1, were created previously to separate the effects of endocrine (serum) IGF-1 from autocrine/paracrine IGF-1. However, LID mice also have two- to threefold increases in GH, and this may contribute to the observed pubertal skeletal phenotype. To clarify the role of GH in skeletal development under conditions of significantly reduced serum IGF-1 levels (but normal tissue IGF-1 levels), we studied the skeletal response of male LID and control mice to GH inhibition by pegvisomant from 4 to 8 weeks of age. Treatment of LID mice with pegvisomant resulted in significant reductions in body weight, femur length (Le), and femur total area (Tt.Ar), as well as further reductions in serum IGF-1 levels by 8 weeks of age, compared with the mean values of vehicle-treated LID mice. Reductions in both Tt.Ar and Le were proportional after treatment with pegvisomant. On the other hand, the relative amount of cortical tissue formed (RCA) in LID mice treated with pegvisomant was significantly less than that in both vehicle-treated LID and control mice, indicating that antagonizing GH action, either directly (through GH receptor signaling inhibition) or indirectly (through further reductions in serum/tissue IGF-1 levels), results in disproportionate reductions in the amount of cortical bone formed. This resulted in bones with significantly reduced mechanical properties (femoral whole-bone stiffness and work to failure were markedly decreased), suggesting that compensatory increases of GH in states of IGF-1 deficiency (LID mice) act to protect against a severe inhibition of bone modeling during growth, which otherwise would result in bones that are too weak for normal and/or extreme loading conditions. © 2011 American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-3179330
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Wiley Subscription Services, Inc., A Wiley Company
record_format MEDLINE/PubMed
spelling pubmed-31793302012-04-01 Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production Courtland, Hayden-William Sun, Hui Beth-On, Mordechay Wu, Yingjie Elis, Sebastien Rosen, Clifford J Yakar, Shoshana J Bone Miner Res Original Article Deficiencies in either growth hormone (GH) or insulin-like growth factor 1 (IGF-1) are associated with reductions in bone size during growth in humans and animal models. Liver-specific IGF-1-deficient (LID) mice, which have 75% reductions in serum IGF-1, were created previously to separate the effects of endocrine (serum) IGF-1 from autocrine/paracrine IGF-1. However, LID mice also have two- to threefold increases in GH, and this may contribute to the observed pubertal skeletal phenotype. To clarify the role of GH in skeletal development under conditions of significantly reduced serum IGF-1 levels (but normal tissue IGF-1 levels), we studied the skeletal response of male LID and control mice to GH inhibition by pegvisomant from 4 to 8 weeks of age. Treatment of LID mice with pegvisomant resulted in significant reductions in body weight, femur length (Le), and femur total area (Tt.Ar), as well as further reductions in serum IGF-1 levels by 8 weeks of age, compared with the mean values of vehicle-treated LID mice. Reductions in both Tt.Ar and Le were proportional after treatment with pegvisomant. On the other hand, the relative amount of cortical tissue formed (RCA) in LID mice treated with pegvisomant was significantly less than that in both vehicle-treated LID and control mice, indicating that antagonizing GH action, either directly (through GH receptor signaling inhibition) or indirectly (through further reductions in serum/tissue IGF-1 levels), results in disproportionate reductions in the amount of cortical bone formed. This resulted in bones with significantly reduced mechanical properties (femoral whole-bone stiffness and work to failure were markedly decreased), suggesting that compensatory increases of GH in states of IGF-1 deficiency (LID mice) act to protect against a severe inhibition of bone modeling during growth, which otherwise would result in bones that are too weak for normal and/or extreme loading conditions. © 2011 American Society for Bone and Mineral Research. Wiley Subscription Services, Inc., A Wiley Company 2011-04 2010-10-06 /pmc/articles/PMC3179330/ /pubmed/20928887 http://dx.doi.org/10.1002/jbmr.265 Text en Copyright © 2011 American Society for Bone and Mineral Research http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Article
Courtland, Hayden-William
Sun, Hui
Beth-On, Mordechay
Wu, Yingjie
Elis, Sebastien
Rosen, Clifford J
Yakar, Shoshana
Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title_full Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title_fullStr Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title_full_unstemmed Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title_short Growth Hormone Mediates Pubertal Skeletal Development Independent of Hepatic IGF-1 Production
title_sort growth hormone mediates pubertal skeletal development independent of hepatic igf-1 production
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179330/
https://www.ncbi.nlm.nih.gov/pubmed/20928887
http://dx.doi.org/10.1002/jbmr.265
work_keys_str_mv AT courtlandhaydenwilliam growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT sunhui growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT bethonmordechay growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT wuyingjie growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT elissebastien growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT rosencliffordj growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production
AT yakarshoshana growthhormonemediatespubertalskeletaldevelopmentindependentofhepaticigf1production